Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) just unveiled an announcement.
Shanghai Fosun Pharmaceutical has announced the establishment of a Target Fund through a partnership with Suzhou Junming, Henan Fujian, Yujian Biomedical, and Zhengzhou Airport Capital. The fund, with a proposed size of RMB2,500 million, aims to invest in innovative enterprises within the medical and life sciences sectors. This move is part of a connected transaction under the Hong Kong Listing Rules, which requires reporting and announcement but not independent shareholder approval.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. operates in the pharmaceutical industry, focusing on the development and manufacturing of medical devices, diagnostics, life sciences, and innovative drugs. The company is involved in the upstream and downstream industrial chains of these sectors.
YTD Price Performance: 10.51%
Average Trading Volume: 5,648
Technical Sentiment Signal: Sell
Current Market Cap: $8B
See more insights into 2196 stock on TipRanks’ Stock Analysis page.